The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation

• DOI: 10.1111/jcpt.13711
• Publication Date: 2022-06-18T09:50:00Z
• Authors: Qinghua Ye; Qianlin Wang; Wenqian Chen; Ruihao Zhang; Ziying Chen; Pengmei Li; Xianglin Zhang; Qingyuan Zhan; Chen Wang
• Keywords: NONMEM; Regimen; Polymyxin B

The presence of extracorporeal membrane oxygenation (ECMO) is suggested to further exacerbate the pharmacokinetics (PK) alterations that occur during critical illness. objectives this study were determine population PK model polymyxin B in critically ill patients with or without ECMO support investigated influence on variability and identify an optimal dosing strategy.Forty-four enrolled, including eight support. Eight serial serum samples collected from each patient at steady state. was determined using NONMEM Monte Carlo simulation performed evaluate exposures different regimens.The analyses included 342 steady-state concentrations a two-compartment for data modelling. In final model, creatinine clearance (CLCR ) significant covariate CL (typical value 1.27 L/h; between-subject 15.1%) did not show impact PK. Additionally, we found parameter estimates mostly similar. Based simulations, dose escalation increased CLCR improved probability achieving required exposure. For ≤ 120 ml/min, dosage regimen 100 mg every 12 h may represent MIC 1 mg/L.The likely be minimal. Our showed potential relationship between CL, should adjusted .